Update on C3 glomerulopathy

Nephrology Dialysis Transplantation

Volumn 31, Issue 5, 2016, Pages 717-725

  Barbour, Thomas D ^a   Ruseva, Marieta M ^a   Pickering, Matthew C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

C3 glomerulopathy; complement; dense deposit; factor H

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H;

AMINO TERMINAL SEQUENCE; CAUSAL ATTRIBUTION; COHORT ANALYSIS; COMPLEMENT ACTIVATION; DIMERIZATION; DISEASE SEVERITY; GLOMERULOPATHY; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; RETROSPECTIVE STUDY; REVIEW; ANIMAL; GLOMERULUS; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT FACTOR H; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS;

EID: 84965119507     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu317     Document Type: Review

References (32)

1. Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079-1089
2. Gale DP, Goicoechea de Jorge E, Cook HT et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376: 794-801
3. Malik TH, Lavin PJ, Goicoechea de Jorge E et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 2012; 23: 1155-1160
4. Ozaltin F, Li B, Rauhauser A et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013; 24: 377-384
5. Tortajada A, Yebenes H, Abarrategui-Garrido C et al. C3 glomerulopathyassociated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 2013; 123: 2434-2446
6. Medjeral-Thomas N, Malik TH, Patel MP et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int 2014; 85: 933-937
7. Chen Q, Wiesener M, Eberhardt HU et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 2013; 124: 145-155
8. Wong EK, Anderson HE, Herbert AP et al. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol 2014; (epub ahead of print)
9. Barbour TD, Pickering MC, Cook HT. Dense deposit disease and C3 glomerulopathy. Semin Nephrol 2013; 33: 493-507
10. Goicoechea de Jorge E, Caesar JJ, Malik TH et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA 2013; 110: 4685-4690
11. Hughes AE, Orr N, Esfandiary H et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of agerelated macular degeneration. Nat Genet 2006; 38: 1173-1177
12. Zhao J, Wu H, Khosravi M et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011; 7: e1002079
13. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327
14. Hou J, Markowitz GS, Bomback AS et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2013; 85: 450-456
15. Bolignano D, Nagler EV, Van Biesen W et al. Providing guidance in the dark: rare renal diseases and the challenge to improve the quality of evidence. NDT 2014; 29: 1628-1632
16. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014; 9: 46-53
17. Zand L, Lorenz EC, Cosio FG et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol 2014; 25: 1110-1117
18. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366: 1161-1163
19. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of densedeposit disease. N Engl J Med 2012; 366: 1163-1165
20. Radhakrishnan S, Lunn A, Kirschfink M et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366: 1165-1166
21. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12: 1046-1051
22. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756
23. Gurkan S, Fyfe B, Weiss L et al. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 2013; 28: 1975-1981
24. Besbas N, Gulhan B, Gucer S et al. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol 2014; 27: 457-460
25. Kerns E, Rozansky D, Troxell ML. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr Nephrol 2013; 28: 2227-2231
26. Rousset-Rouvière C, Cailliez M, Garaix F et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014; 29: 1107-1111
27. Ozkaya O, Nalcacioglu H, Tekcan D et al. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 2014; 29: 1283-1287
28. Berthe-Aucejo A, Sacquépée M, Fila M et al. Blockade of alternative complement pathway in dense deposit disease. Case Rep Nephrol 2014; 201568
29. Sánchez-Moreno A, De la Cerda F, Cabrera R et al. Eculizumab in densedeposit disease after renal transplantation. Pediatr Nephrol 2014; 29: 2055-2059
30. Herlitz LC, Bomback AS, Markowitz GS et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 1229-1237
31. Zhang Y, Nester CM, Holanda DG et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 2013; 24: 1820-1829
32. Giaime P, Daniel L, Burtey S. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy. Clin Nephrol 2014; (epub ahead of print)